Study limitations
HFpEF, diastolic dysfunction, cardiometabolic syndrome, LV stiffness
DIASTOLIC DYSFUNCTION, OBESE, CARDIOMETABOLIC SYNDROME
In the present study, we did not observe a higher LV stiffness constant β in vehicle‐treated obese ZSF1 rats, in contrast to previous reports (Hamdani et al., Furthermore, although our data show that GGA attenuates the progression of diastolic dysfunction in obese ZSF1 rats (Figure Finally, we studied male rats exclusively to investigate cardiac and cellular function in a model of the cardiometabolic syndrome that is known to progress to HFpEF. Although HFpEF is more prevalent in women, we aimed to eliminate the influence of sex differences that could impact the quality and interpretation of our analysis. Because we used recombinant HSPB1 and HSPB5 in our cardiomyocyte experiments, we are confident that any possible sex differences that can limit the interpretation of our results is low. These results provide proof‐of‐concept evidence for GGA's downstream effects on cardiomyocyte function.